Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emer... (s 11 hours for abdominal 24 hours for fa...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care

Date:11/7/2009

s, 11 hours for abdominal, 24 hours for facial and 25 hours for peripheral attacks. No drug-related serious adverse events have been reported to date, nor were any rebound effects observed following C1-INH administration.

About CSL Behring

CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring.com.

    Contact:
    Sheila A. Burke, Director, Communications & Public Relations
    Worldwide Commercial Operations
    CSL Behring
    C: 484-919-2618
    O: 610-878-4209
    Sheila.Burke@cslbehring.com

SOURCE CSL Behring

SOURCE CSL Behring
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
2. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
3. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
4. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
5. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
6. Changing Paradigms in Hereditary Angioedema: A Focus on Prompt Diagnosis and New Therapies
7. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
8. Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma

Post Your Comments:

(Date:11/20/2009)... , PLYMOUTH MEETING, Pa., Nov. 20 /PRNewswire...Times article that questions why currently availa... cancers are being ignored, ECRI Institute, an ind...dmap to the evidence on Finasteride for Preventio...he November 13, 2009, New York Times article, " ...

(Date:11/19/2009)... , ARDEE, Ireland, Nov. 19 Warn...he pricing of its previously announced secondary o...price to the public of $22.25 per share. The sell...n Capital Partners, DLJ Merchant Banking, J.P. Mor...H. Lee Partners, L.P., certain other institutional...

(Date:11/19/2009)... , TAINAN, Taiwan, Nov. 19 /PRNewswire-Asi...ive pharmaceutical ingredients (APIs), announced t...mpound Safety Certification from,SafeBridge(R) Con...rm,s,competency and proficiency in the safe handli...Is), and applies to specific laboratories and,prod...

Breaking Medicine Technology:ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2 ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3 Warner Chilcott Prices Secondary Equity Offering 2 Warner Chilcott Prices Secondary Equity Offering 3 Warner Chilcott Prices Secondary Equity Offering 4 ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2 Harold Hank Gardner M D Named in the Future Health 100 56303 1 Harold Hank Gardner M D Named in the Future Health 100 56303 2 Pharmacists Urge the Public to Begin Getting Immunized 56298 1 Pharmacists Urge the Public to Begin Getting Immunized 56298 2 Pharmacists Urge the Public to Begin Getting Immunized 56298 3 Stand Up for Health Care 21 A Labor Day Message From RWDSU President Stuart Appelbaum 56294 1 Stand Up for Health Care 21 A Labor Day Message From RWDSU President Stuart Appelbaum 56294 2 Stand Up for Health Care 21 A Labor Day Message From RWDSU President Stuart Appelbaum 56294 3

[0] ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists [0] Warner Chilcott Prices Secondary Equity Offering [0] ScinoPharm Announces SafeBridge Potent Compound Safety Certification

...ive Phase 2a Trial, WALTHAM, Mass., June 12 Repl...that based on feedback from the Food and,Drug Admi...2b clinical,trial of RG2417, an oral formulation o... this year. This will be a multi-center, parallel ...proximately 150 patients with,bipolar disorder wil...

...vement in disease activity through three yea...crease in adverse events, malignancies, infections... over time -, ROCKVILLE, Md., June 12 Human Geno... the presentation of results,from a long- term Pha...R),(belimumab) was associated with sustained impro...

Other Medicine Technology:Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 2 Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 3 Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 4 Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 5 Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 2 Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 3 Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 4 Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 5 Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 6 Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 7

Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus

(Date:11/20/2009)..., , NEW YORK, Nov. 20 Re...h report is available in its catalogue. ,, Onc...t Forecast to 2013 ,, http://www.reportlinke...chmarks-and-Market-Forecast-to-2013.html#utm_sourc...newswire ,, Comprehensive Forecasts and Detai...

(Date:11/20/2009)..., , NEW YORK, Nov. 20 Re...h report is available in its catalogue. ,, Ima...ttp://www.reportlinker.com/p0164325/Imaging-Agents...swire&utm_medium=pr&utm_campaign=prnewswir...nized the visualization of organs within the human...

(Date:11/20/2009)..., , HINESBURG, Vt., Nov. 20 K...mpany that specializes in creating sophisticated m...ay announced the launch www.infectioncontrolsourc...care administrators with a comprehensive database ..., "Our mission at Kestrel is to educate healthcar...

(Date:11/20/2009)..., , LOS ANGELES, Nov. 20 As...al feasts, more than 1.25 million people in Los An...rstand the magnitude of the problem, that,s nearly..., people you see every day are hungry - and the si...continues to increase. ,, The Jewish Federatio...

(Date:11/20/2009)...y molecule identified by researchers , ,...may be moving closer to better treatments for bovi...cow disease, and the related condition called Creu...can-1 is crucial to the development of mad cow dis...erstanding its role could help scientists figure o...

[0] Reportlinker Adds Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013 [0] Reportlinker Adds Imaging Agents - A Worldwide Market Review [0] Infection Prevention Online Community Site Launches - Focused on Product Selection [0] The Jewish Federation Unveils Blueprint to End Hunger in Los Angeles [0] Unraveling the 'Mad Cow' Mystery

...ief that infants' brains don't divide into left-br...study finds the brain's left hemisphere plays the ... beginning almost immediately after birth. Rese...e fMRI has been used to study infants. It is a non...

...osed among men in the United States -- affecting n... treatment options, but new research shows there m... Doctors hope that the drug -- finasteride -- wil... conversion to DHT -- a more active form of the ho...

...ugs used for acute asthma attacks might be causing... studied the use of bronchodilators known as beta-...ry treatment used to relieve acute asthma attacks.... Whatever the mode of administration, they work by...

... blood pressure and heart failure may also benefit...er risk for heart attacks and stroke. Researcher...women from the Heart Outcomes Prevention Evaluatio...ng stroke, peripheral arterial disease, or diabete...

...he risk of dementia , some find light to moderate ... others still find no association at all. In a ... between the ages of 65 and 79 who were followed o...ltogether were both about twice as likely as those...

...ely low body fat whether due to strenuous exercise...from treatment with the appetite-and-weight-regula...ptin may be useful in treating some instances of i...g how much energy is available to the body for imp...

Other Medicine News:Health News:fMRI Offers Insight Into An Infants Brain 2

fMRI Offers Insight Into An Infants Brain Prevention Of Prostate Cancer The Adverse Effects Of Asthma Medication Heart Drug Also Effective In Preventing Specific Causes Of Death Could Midlife Alcohol Drinking Lead To Dementia ?Hormone Leptin Found To Be Effective In Treating Women With Infertility Problems

...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...

Medicine Products:

Phosphate, Serum or Plasma Phenylalanine Test Phensuximide, Urine Phenolphthalein, Fecal

Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emer...(s 11 hours for abdominal 24 hours for fa...),Health